journal article·2022-08-04Open access

The Uroprotective Efficacy of Total Ginsenosides in Chinese Ginseng on Chemotherapy with Cyclophosphamide

Yung-Hsiang Chen, Wen-Chi Chen, Szu-Ju Chen, Shih-Jing Wang, Po-Len Liu, Ming-Yen Tsai, Chun-Ting Liu, Der-Cherng Chen, Huey-Yi Chen

Applied Sciences· Volume 12· Issue 15

Abstract

Hemorrhagic cystitis is a recognizable complication of cyclophosphamide (CYP) attributable to its lively metabolite acrolein, which produces urothelial injury. The study intended to examine the uroprotective efficacy of total ginsenosides in Chinese ginseng (TGCG) in CYP-induced hemorrhagic cystitis. In total, 24 virgin female rats were randomized into four groups as follows: group 1 (control group; injected with normal saline), group 2 (injected with CYP plus a placebo with normal saline), group 3 (given CYP and TGCG (200 mg/kg)), and group 4 (given CYP and 2-mercaptoethane sulfonate sodium (Mesna, 30 mg/kg)). An evaluation by cystometry was conducted. Values of the voiding interval were assessed in anesthetized rats and histological examinations of the bladders were measured. In the cystometry analysis, the voiding interval was significantly reduced in the CYP group. TGCG and Mesna significantly increased in the voiding interval values, individually. Bladder edema and urothelial injury were examined after contact with CYP. Contrasted to the group given CYP, CYP-induced hemorrhagic cystitis, TGCG significantly increased the urothelial thickness, and significantly reduced scores of mucosal break and submucosal edema in the bladder. In conclusion, these findings mean that the treatment with TGCG in CYP rats can avoid hemorrhagic cystitis. TGCG decreases urothelial injury. TGCG may participate as the chief character of uroprotection in CYP-induced hemorrhagic cystitis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ginseng Biological Effects and Applications · Ovarian function and disorders · Chemotherapy-induced organ toxicity mitigation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Graduate Institute of Integrated Medicine, College of Chinese Medicine, School of Medicine, China Medical University, Taichung 40402, Taiwan

Department of Medical Research, Department of Urology, Department of Neurosurgery, Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung 40447, Taiwan

Department of Psychology, College of Medical and Health Science, Asia University, Taichung 41354, Taiwan

Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung 40705, Taiwan

Department of Respiratory Therapy, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan

Department of Chinese Medicine, Dali Branch, Jen-Ai Hospital, Taichung 41265, Taiwan

Funding

China Medical University, Taichung, Taiwan · Ministry of Science and Technology, Taiwan

References (50)

Show source-provided references
1. Bounias, D., Singh, A., Bakas, S., Pati, S., Rathore, S., Akbari, H., Bilello, M., Greenberger, B.A., Lombardo, J., and Chitalia, R.D. (2021). Interactive Machine Learning-Based Multi-Label Segmentation of Solid Tumors and Organs. Appl. Sci., 11.10.3390/app11167488 ↗
2. Cyclophosphamide and cancer: Golden anniversary10.1038/nrclinonc.2009.146 ↗
3. Hemorrhagic Cystitis: Treatment with Hyperbaric Oxygen Therapy in Patients with Acute Lymphoblastic Leukemia
4. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients10.1002/1097-0142(19880201)61:3<451::AID-CNCR2820610308>3.0.CO;2-G ↗
5. Cyclophosphamide and urinary bladder toxicity
6. Urinary bladder complications with cyclophosphamide therapy10.1001/archinte.1976.03630050090015 ↗
7. Comparison of the uroprotective efficacy of mesna and HBO treatments in cyclophosphamide-induced hemorrhagic cystitis10.1016/S0022-5347(01)68238-7 ↗
8. Cyclophosphamide cystitis--identification of acrolein as the causative agent10.1016/0006-2952(79)90222-3 ↗
9. The development of mesna for regional detoxification10.1016/S0305-7372(83)80005-X ↗
10. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation10.1200/JCO.1991.9.11.2016 ↗
11. Clinical overview of mesna10.1016/S0305-7372(83)80026-7 ↗
12. Participation of TNF-alpha and IL-1 in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis
13. Involvement of nitric oxide in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis
14. Development of natural antitumor agents10.1016/j.biomed.2013.06.001 ↗
15. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer10.1111/j.1745-7254.2008.00869.x ↗
16. Treatment of stress urinary incontinence by ginsenoside Rh210.1142/S0192415X14500529 ↗
17. Panax ginseng and its ginsenosides: Potential candidates for the prevention and treatment of chemotherapy-induced side effects10.1016/j.jgr.2021.03.001 ↗
18. Antihyperglycemic effects of total ginsenosides from leaves and stem of Panax ginseng10.1111/j.1745-7254.2005.00156.x ↗
19. Ginsenoside Rh2 induces human hepatoma cell apoptosisvia bax/bak triggered cytochrome C release and caspase-9/caspase-8 activation10.3390/ijms131215523 ↗
20. Antioxidant activity in medicinal plants associated with the symptoms of diabetes mellitus used by the indigenous peoples of the North American boreal forest10.1016/S0378-8741(02)00180-0 ↗
21. Wrobel, A., Zapala, L., Kluz, T., Rogowski, A., Misiek, M., Juszczak, K., Sienko, J., Gold, D., Stangel-Wojcikiewicz, K., and Poleszak, E. (2021). The Potential of Asiatic Acid in the Reversion of Cyclophosphamide-Induced Hemorrhagic Cystitis in Rats. Int. J. Mol. Sci., 22.10.3390/ijms22115853 ↗
22. The effect of O-1602, a GPR55 agonist, on the cyclophosphamide-induced rat hemorrhagic cystitis10.1016/j.ejphar.2020.173321 ↗
23. Rho kinase inhibition ameliorates cyclophosphamide-induced cystitis in rats10.1007/s00210-017-1361-8 ↗
24. Uroprotective effect of pantoprazole against cyclophosphamide-induced cystitis in mice10.1007/s00520-019-04731-2 ↗
25. Cyclophosphamide-induced cystitis in freely-moving conscious rats: Behavioral approach to a new model of visceral pain10.1016/S0022-5347(05)67495-2 ↗
26. Relevance of the cyclophosphamide-induced cystitis model for pharmacological studies targeting inflammation and pain of the bladder10.1016/j.ejphar.2013.03.008 ↗
27. Effects of anesthesia on cystometry and leak point pressure of the female rat10.1016/S0024-3205(01)01182-1 ↗
28. Proteomic analysis related to stress urinary incontinence following vaginal trauma in female mice10.1016/j.ejogrb.2013.08.034 ↗
29. Stress urinary incontinence following vaginal trauma involves remodeling of urethral connective tissue in female mice10.1016/j.ejogrb.2012.04.012 ↗
30. A mouse model of simulated birth trauma induced stress urinary incontinence10.1002/nau.20509 ↗
31. Functional characterization of a chronic cyclophosphamide-induced overactive bladder model in mice10.1002/nau.21180 ↗
32. Protective effect of Flos carthami extract against ethylene glycol-induced urolithiasis in rats10.1007/s00240-012-0472-4 ↗
33. Ginkgo biloba extract inhibits endotoxin-induced human aortic smooth muscle cell proliferation via suppression of toll-like receptor 4 expression and NADPH oxidase activation10.1021/jf062945r ↗
34. Appearance of acanthosis nigricans may precede obesity: An involvement of the insulin/IGF receptor signaling pathway10.1016/j.biomed.2013.04.001 ↗
35. Increased IL-8 and IL-1β in the bile of acute cholecystitis patients10.1016/j.biomed.2013.08.001 ↗
36. Genetic variations within the PSORS1 region affect Kawasaki disease development and coronary artery aneurysm formation10.1016/j.biomed.2013.03.001 ↗
37. Prevention of cyclophosphamide-induced hemorrhagic cystitis10.1016/0090-4295(82)90633-1 ↗
38. Personalized medicine: A paradigm shift in healthcare10.1016/j.biomed.2012.12.005 ↗
39. The relaxant effect of ginseng saponin on the bladder and prostatic urethra: An in vitro and in vivo study10.1159/000337206 ↗
40. Cyclophosphamide treatment causes impairment of sperm and its fertilizing ability in mice10.1016/j.tox.2006.01.027 ↗
41. Studies of the effects and mechanisms of ginsenoside Re and Rk3 on myelosuppression induced by cyclophosphamide10.1016/j.jgr.2018.07.009 ↗
42. Panax ginseng is superior to vitamin E as a hepatoprotector against cyclophosphamide-induced liver damage10.1016/j.ctim.2019.08.005 ↗
43. Cyclophosphamide-induced testicular toxicity ameliorate by American ginseng treatment: An experimental study
44. Characteristics of TRK-130 (Naltalimide), a novel opioid ligand, as a new therapeutic agent for overactive bladder10.1124/jpet.114.214031 ↗
45. Role of pigment epithelium-derived factor in stem/progenitor cell-associated neovascularization10.1155/2012/871272 ↗
46. Fourteen-day administration of corticosterone may induce detrusor overactivity symptoms10.1007/s00192-016-3027-3 ↗
47. A novel urodynamic model for lower urinary tract assessment in awake rats10.1111/bju.13039 ↗
48. Ginsenosides for cardiovascular diseases; update on pre-clinical and clinical evidence, pharmacological effects and the mechanisms of action10.1016/j.phrs.2021.105481 ↗
49. Pharmacological Effects of Active Components of Chinese Herbal Medicine in the Treatment of Alzheimer’s Disease: A Review10.1142/S0192415X16500853 ↗
50. Progress on the Elucidation of the Antinociceptive Effect of Ginseng and Ginsenosides in Chronic Pain10.3389/fphar.2022.821940 ↗